NDA 020965 · Sun Pharm Inds INC
Levulan
Aminolevulinic Acid Hydrochloride · Topical
NovelLast checked: Nov 20, 2026Latest source record: May 9, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Dec 3, 1999
Approved uses
3
Original approval plus efficacy supplements
Registered trials
200
40 Phase 3, 19 recruiting
FAERS reports
1,433
182 serious, 9 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 12, 2024.
The LEVULAN KERASTICK for topical solution plus blue light illumination using the BLU-U Blue Light Photodynamic Therapy Illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses of the face, scalp, or upper extremities. LEVULAN KERASTICK for topical solution, a porphyrin precursor, plus blue light illumination using the BLU-U Blue Light Photodynamic Therapy Illuminator is indicated for photodynamic therapy (treatment) of minimally to moderately thick actinic keratoses of the face or scalp, or actinic keratoses of the upper extremities. ( 1 )
Mechanism: Following the application of LEVULAN KERASTICK topical solution, photosensitization occurs through the metabolic conversion of aminolevulinic acid to protoporphyrin IX (PpIX), a photosensitizer, which accumulates in the skin. When exposed to light of appropriate wavelength and energy, the accumulated photoactive porphyrins produce a photodynamic reaction, resulting in a cytotoxic process dependent upon the simultaneous presence of oxygen. The absorption of light results in an excited state of porphyrin molecules, and subsequent spin transfer from photoreactive porphyrins to molecular oxygen...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 6, 2018 Supplement 15 · Efficacy LabelLetter
- Mar 12, 2010 Supplement 7 · Efficacy LetterLabel
- Dec 3, 1999 Original approval · Type 1 - New Molecular Entity LetterReviewLabel
1 products under this application
- LEVULAN · AMINOLEVULINIC ACID HYDROCHLORIDE 20% · SOLUTION, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Aminolevulinic Acid" as an intervention, any sponsor and status, largest first.
- Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence CystoscopyPivotal-lookingCompleted
PhotocureIndustry
NCT00233402 · 789 participants · Start Jan 2005 · Primary completion Jul 2008
Drug: Hexvix · For: Bladder Cancer
Sites: Stanford, California; Gainesville, Florida; Miami, Florida · 25 sites in all
- Photodynamic Diagnosis (PDD) in Flexible CystoscopyPivotal-lookingCompleted
Jørgen Bjerggaard JensenAcademic, hospital or other
NCT02660190 · 696 participants · Start Feb 2016 · Primary completion Dec 2017
Drug: hexaminoavolunate · For: Bladder Cancer; Recurrence; PDD
Sites: Herlev, Denmark; Holstebro, Denmark
- Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic TherapyPivotal-lookingCompleted
Biofrontera Bioscience GmbHIndustry
NCT02799069 · 571 participants · Start Apr 2008 · Primary completion Aug 2009
Drug: BF-200 ALA; MAL Cream and 1 more · For: Actinic Keratosis
- Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the FacePivotal-lookingCompleted
Galderma R&DIndustry
NCT04085367 · 557 participants · Start Sep 30, 2019 · Primary completion Mar 3, 2021
Drug: MAL 16.8% cream; MAL Vehicle Cream · For: Actinic Keratoses
Sites: Tucson, Arizona; Fort Smith, Arkansas; Encinitas, California · 60 sites in all
- ALA-induced PpIX Fluorescence During Brain Tumor ResectionActive, not recruiting
David W. RobertsAcademic, hospital or other
NCT02191488 · 540 participants (planned) · Start Jul 2014 · Primary completion Dec 31, 2027
Drug: 5-aminolevulinic acid · For: Brain Tumors
Sites: Lebanon, New Hampshire
- Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic AcidPivotal-lookingCompleted
medac GmbHIndustry
NCT00241670 · 415 participants · Start Oct 1999 · Primary completion Jul 2004
Drug: 5-aminolevulinic acid (5-ALA) · For: Brain Cancer; Brain Tumors; Cancer of Brain and 2 more
- Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)Pivotal-lookingRecruiting
University of Roma La SapienzaAcademic, hospital or other
NCT05962541 · 327 participants (planned) · Start Dec 22, 2025 · Primary completion Dec 2028
Drug: PDD-TURBT with hexaminolevulinate (Hexvix®) · For: Non-muscle-invasive Bladder Cancer; Non-Muscle Invasive Bladder Urothelial Carcinoma; High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
Sites: Rome, Italy
University Hospital TuebingenAcademic, hospital or other
NCT02379572 · 315 participants · Start Jun 2015 · Primary completion Jun 2020
Drug: 5-ALA-guided surgery · For: Glioblastoma
Sites: Bonn, Germany; Cologne, Germany; Dresden, Germany · 15 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective244
- wrong technique in product usage process182
- poor quality product administered177
- product quality issue153
- product dose omission issue114
- erythema102
- accidental exposure to product79
- off label use78
- pain63
- product physical issue62
- blister48
- application site pain42
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 3 |
| 2013 | 6 |
| 2014 | 6 |
| 2015 | 13 |
| 2016 | 77 |
| 2017 | 64 |
| 2018 | 87 |
| 2019 | 77 |
| 2020 | 172 |
| 2021 | 66 |
| 2022 | 115 |
| 2023 | 167 |
| 2024 | 212 |
| 2025 | 235 |
| 2026 | 133 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Levulan (Aminolevulinic Acid HCl)
2024 spending
$211K
Beneficiaries
359
439 claims
Per beneficiary
$586
$384.83 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $140,395 |
| 2021 | $161,219 |
| 2022 | $196,105 |
| 2023 | $309,611 |
| 2024 | $210,503 |
Part B: Levulan (Aminolevulinic Acid HCL) · HCPCS J7308
2024 spending
$42.0M
Beneficiaries
65,877
96,953 claims
Per beneficiary
$637
2024 ASP limit $395.27 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $36,413,945 |
| 2021 | $36,088,117 |
| 2022 | $37,902,550 |
| 2023 | $39,915,627 |
| 2024 | $41,988,895 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Acne and the cutaneous microbiome: A systematic review of mechanisms and implications for treatments.
Podwojniak A, Tan IJ, Sauer J, et al. · J Eur Acad Dermatol Venereol 2025 · Systematic Review
- Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
Balwani M, Sardh E, Ventura P, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
- Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.
Stummer W, Pichlmeier U, Meinel T, et al. · Lancet Oncol 2006 · Clinical Trial, Phase III, Multicenter Study
- Photodynamic therapy guidelines for the management of oral leucoplakia.
Chen Q, Dan H, Tang F, et al. · Int J Oral Sci 2019 · Research Support, Non-U.S. Gov't, Systematic Review
- Effective treatment of actinic keratosis on the hands with red light photodynamic therapy using BF-200 ALA.
Ulrich M, Reinhold U, Dominicus R, et al. · Photodiagnosis Photodyn Ther 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Glycolysis inhibition improves photodynamic therapy response rates for equine sarcoids.
Golding JP, Kemp-Symonds JG, Dobson JM · Vet Comp Oncol 2017 · Clinical Trial
Sponsor: Sun Pharm Inds INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.